These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11245553)

  • 21. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic studies on desogestrel administered alone and in combination with ethinylestradiol.
    Cullberg G
    Acta Obstet Gynecol Scand Suppl; 1985; 133():1-30. PubMed ID: 3161265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Yasmin: the reason why.
    Thorneycroft IH
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin.
    Song S; Chen JK; He ML; Fotherby K
    Contraception; 1989 Apr; 39(4):385-99. PubMed ID: 2498034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
    Dibbelt L; Knuppen R; Jütting G; Heimann S; Klipping CO; Parikka-Olexik H
    Contraception; 1991 Jan; 43(1):1-21. PubMed ID: 1825969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives.
    Nielsen CH; Poulsen HK; Teisner B; Thorsen P; Hau J; Westergaard JG
    Eur J Obstet Gynecol Reprod Biol; 1993 Sep; 51(1):63-71. PubMed ID: 7506680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yasmin--a new oral contraceptive, a new progestogen: the reasons why.
    Mansour D
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():9-16. PubMed ID: 11246601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.
    Wiesinger H; Eydeler U; Richard F; Trummer D; Blode H; Rohde B; Diefenbach K
    Clin Drug Investig; 2012 Oct; 32(10):673-84. PubMed ID: 22909145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
    Gaspard U; Scheen A; Endrikat J; Buicu C; Lefebvre P; Gerlinger C; Heithecker R
    Contraception; 2003 Jun; 67(6):423-9. PubMed ID: 12814810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol.
    Rosenbaum P; Schmidt W; Helmerhorst FM; Wuttke W; Rossmanith W; Freundl F; Thomas K; Grillo M; Wolf A; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):16-24. PubMed ID: 10836659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gestodene-containing contraceptives.
    Kuhl H; Jung-Hoffmann C; Wiegratz I
    Clin Obstet Gynecol; 1995 Dec; 38(4):829-40. PubMed ID: 8616979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido.
    Oranratanaphan S; Taneepanichskul S
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S17-22. PubMed ID: 17726807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
    De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
    Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
    Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives.
    Mawet M; Maillard C; Klipping C; Zimmerman Y; Foidart JM; Coelingh Bennink HJ
    Eur J Contracept Reprod Health Care; 2015; 20(6):463-75. PubMed ID: 26212489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
    Hammond GL; Bocchinfuso WP; Orava M; Smith CL; van den Ende A; van Enk A
    Contraception; 1994 Oct; 50(4):301-18. PubMed ID: 7813219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.